RayKnowChina Research Map
Shortlist

Not yet recruitingLung cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer

An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Tianjin Medical University Cancer Institute & Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07244926, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 8

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (8 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Histologically or cytologically confirmed locally advanced or metastatic non-squamous NSCLC (stage IIIB/C or IV not amenable to curative treatment)

    Inclusion criterion 2

  3. Disease progression after first-line platinum-based chemotherapy combined with anti-PD-(L)1 therapy.

    Inclusion criterion 4

    Previously received any of the following treatments (including in the adjuvant or neoadjuvant setting): a) Therapy targeting TROP2. b) Any drug therapy containing a topoisomerase I inhibitor, including Antibody-Drug Conjugate (ADC) therapy. c) Anti-angiogenic agents.

    Exclusion criterion 2

    History of other malignancies within 3 years prior to dosing (except for tumors cured with local therapy, such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, carcinoma in situ of the cervix, etc.).

    Exclusion criterion 6

    Major surgery within 4 weeks prior to dosing or anticipated need for major surgery during the study period.

    Exclusion criterion 24

    Radiation therapy to lung lesions with a total dose > 30 Gy within 6 months prior to dosing; non-thoracic radiotherapy with a total dose > 30 Gy or extensive radiotherapy (including radionuclide therapy such as Strontium-89) within 4 weeks prior to dosing; palliative radiotherapy for symptom control is allowed but must be completed at least 2 weeks before the first dose.

    Exclusion criterion 27

  4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 within 7 days prior to administration.

    Inclusion criterion 6

  5. Negative for EGFR sensitizing mutations [no exon 19 deletion (19-Del) or exon 21 point mutation (L858R mutation)] and ALK fusion gene, and no known actionable gene alterations in ROS1, NTRK, BRAF, MET, KRAS, HER2, or RET.

    Inclusion criterion 3

  6. At least one measurable lesion according to RECIST v1.1.

    Inclusion criterion 5

  7. Histologically or cytologically confirmed squamous cell NSCLC or mixed with small cell lung cancer, neuroendocrine carcinoma, or carcinosarcoma components.

    Exclusion criterion 1

    Positive human immunodeficiency virus (HIV) test or history of acquired immunodeficiency syndrome (AIDS); known active syphilis infection.

    Exclusion criterion 22

  8. Agreement to use effective medical contraception methods from the time of signing the informed consent form until 6 months after the last dose for female subjects of childbearing potential and male subjects with partners of childbearing potential.

    Inclusion criterion 9

    Pregnant or lactating women.

    Exclusion criterion 30

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07244926, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age ≥18 years old, regardless of gender
  • Histologically or cytologically confirmed locally advanced or metastatic non-squamous NSCLC (stage IIIB/C or IV not amenable to curative treatment)
  • Negative for EGFR sensitizing mutations [no exon 19 deletion (19-Del) or exon 21 point mutation (L858R mutation)] and ALK fusion gene, and no known actionable gene alterations in ROS1, NTRK, BRAF, MET, KRAS, HER2, or RET.
  • Disease progression after first-line platinum-based chemotherapy combined with anti-PD-(L)1 therapy.
  • At least one measurable lesion according to RECIST v1.1.
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 within 7 days prior to administration.
  • Expected life expectancy ≥ 12 weeks.
  • Adequate organ and bone marrow function.
  • Agreement to use effective medical contraception methods from the time of signing the informed consent form until 6 months after the last dose for female subjects of childbearing potential and male subjects with partners of childbearing potential.
  • Join the study voluntarily, signs the informed consent form, and is able to comply with the visits and related procedures stipulated in the protocol.

Exclusion Criteria:

  • Histologically or cytologically confirmed squamous cell NSCLC or mixed with small cell lung cancer, neuroendocrine carcinoma, or carcinosarcoma components.
  • Previously received any of the following treatments (including in the adjuvant or neoadjuvant setting): a) Therapy targeting TROP2. b) Any drug therapy containing a topoisomerase I inhibitor, including Antibody-Drug Conjugate (ADC) therapy. c) Anti-angiogenic agents.
  • Requirement for strong inhibitors or inducers of Cytochrome P450 3A4 (CYP3A4) within 2 weeks prior to the first dose or during the study period.
  • Documented severe dry eye syndrome, severe meibomian gland disease and/or blepharitis, or history of corneal disease that prevents/delays corneal healing.
  • Known leptomeningeal metastasis, brainstem metastasis, spinal cord metastasis and/or compression, or active central nervous system (CNS) metastases. Subjects with brain metastases previously treated with local therapy can participate if they are clinically stable for at least 4 weeks prior to dosing and do not require corticosteroids or anticonvulsants for at least 14 days; subjects with untreated asymptomatic brain metastases may be enrolled after investigator assessment.
  • History of other malignancies within 3 years prior to dosing (except for tumors cured with local therapy, such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, carcinoma in situ of the cervix, etc.).
  • Presence of severe cardiovascular or cerebrovascular diseases or risk factors.
  • Uncontrolled systemic diseases, as judged by the investigator.
  • Urinalysis shows urine protein ≥ ++ and confirmed 24-hour urine protein quantification > 1.0 g.
  • History of (non-infectious) interstitial lung disease (ILD) or non-infectious pneumonitis requiring steroid treatment, current ILD or non-infectious pneumonitis, or suspected ILD or non-infectious pneumonitis that cannot be ruled out by imaging at screening.
  • Clinically severe pulmonary impairment due to concurrent pulmonary diseases.
  • Subjects with active chronic inflammatory bowel disease, gastrointestinal obstruction, severe ulcer, gastrointestinal perforation, intra-abdominal abscess, or acute gastrointestinal bleeding.
  • Tumor invasion or compression of surrounding vital organs and blood vessels accompanied by related symptoms (e.g., superior vena cava syndrome), or risk of esophagotracheal fistula or esophagopleural fistula.
  • History of bleeding tendency or coagulation disorder and/or clinically significant bleeding symptoms or risks within 4 weeks prior to the first dose.
  • Use of aspirin (>325 mg/day) or treatment with dipyridamole or clopidogrel within 2 weeks prior to the first dose.
  • Use of full-dose oral or intravenous anticoagulants or thrombolytic agents within 2 weeks prior to the first dose.
  • Biopsy or other minor surgery (excluding placement of vascular access devices) within 7 days prior to the first dose.
  • Toxicity from previous anti-tumor therapy has not recovered to ≤ Grade 1 or the level specified in the eligibility criteria (except for toxicities judged by the investigator to pose low safety risks, such as alopecia, fatigue, etc.).
  • Known active tuberculosis. Subjects suspected of having active tuberculosis require clinical evaluation to exclude it.
  • History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
  • Active Hepatitis B or Hepatitis C. Note: Subjects who are HBsAg positive are required to receive anti-hepatitis B virus therapy during the study treatment period.
  • Positive human immunodeficiency virus (HIV) test or history of acquired immunodeficiency syndrome (AIDS); known active syphilis infection.
  • Known allergy to the investigational drug or any of its components, history of severe hypersensitivity reactions to other biological agents.
  • Major surgery within 4 weeks prior to dosing or anticipated need for major surgery during the study period.
  • Severe infection within 4 weeks prior to dosing, active infection requiring systemic anti-infective therapy within 2 weeks prior to dosing.
  • Non-specific immunomodulatory therapy within 2 weeks prior to dosing.
  • Radiation therapy to lung lesions with a total dose > 30 Gy within 6 months prior to dosing; non-thoracic radiotherapy with a total dose > 30 Gy or extensive radiotherapy (including radionuclide therapy such as Strontium-89) within 4 weeks prior to dosing; palliative radiotherapy for symptom control is allowed but must be completed at least 2 weeks before the first dose.
  • Administration of live vaccines within 30 days prior to dosing, or planned administration of live vaccines during the study period.
  • Rapid deterioration of condition during the screening period prior to dosing.
  • Pregnant or lactating women.
  • Local or systemic diseases caused by non-malignant conditions, or diseases or symptoms secondary to the tumor, that could lead to high medical risk and/or uncertainty in survival assessment.
  • Any condition that, in the investigator's judgment, interferes with the evaluation of the investigational product, subject safety, or interpretation of study results, or any other situation where the investigator considers the subject unsuitable for participation in this study.

Quoted from ClinicalTrials.gov, NCT07244926, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07244926, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07244926